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Abstract
Background:  Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) selectively
induces apoptosis in cancer cells but not in normal cells. Despite this promising feature, TRAIL resistance
observed in cancer cells seriously challenged the use of TRAIL as a death ligand in gene therapy. The
current dispute concerns whether or not TRAIL receptor expression pattern is the primary determinant
of TRAIL sensitivity in cancer cells. This study investigates TRAIL receptor expression pattern and its
connection to TRAIL resistance in breast cancer cells. In addition, a DcR2 siRNA approach and a
complementary gene therapy modality involving IKK inhibition (AdIKKβ KA) were also tested to verify if
these approaches could sensitize MCF7 breast cancer cells to adenovirus delivery of TRAIL (Ad5hTRAIL).
Methods: TRAIL sensitivity assays were conducted using Molecular Probe's Live/Dead Cellular Viability/
Cytotoxicity Kit following the infection of breast cancer cells with Ad5hTRAIL. The molecular mechanism
of TRAIL induced cell death under the setting of IKK inhibition was revealed by Annexin V binding. Novel
quantitative Real Time RT-PCR and flow cytometry analysis were performed to disclose TRAIL receptor
composition in breast cancer cells.
Results: MCF7 but not MDA-MB-231 breast cancer cells displayed strong resistance to adenovirus
delivery of TRAIL. Only the combinatorial use of Ad5hTRAIL and AdIKKβ KA infection sensitized MCF7
breast cancer cells to TRAIL induced cell death. Moreover, novel quantitative Real Time RT-PCR assays
suggested that while the level of TRAIL Decoy Receptor-4 (TRAIL-R4) expression was the highest in
MCF7 cells, it was the lowest TRAIL receptor expressed in MDA-MB-231 cells. In addition, conventional
flow cytometry analysis demonstrated that TRAIL resistant MCF7 cells exhibited substantial levels of
TRAIL-R4 expression but not TRAIL decoy receptor-3 (TRAIL-R3) on surface. On the contrary, TRAIL
sensitive MDA-MB-231 cells displayed very low levels of surface TRAIL-R4 expression. Furthermore, a
DcR2 siRNA approach lowered TRAIL-R4 expression on surface and this sensitized MCF7 cells to TRAIL.
Conclusion: The expression of TRAIL-R4 decoy receptor appeared to be well correlated with TRAIL
resistance encountered in breast cancer cells. Both adenovirus mediated IKKβ KA expression and a DcR2
siRNA approach sensitized MCF7 breast cancer cells to TRAIL.
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Background
Cancer still appears to be a challenging disease to treat.
According to most recent estimates, more than 10 million
new cancer cases were reported in the year 2000 killing
around 6 million people [1]. In addition, 10 % of all can-
cers appear to be the breast cancer. Being the most fre-
quently diagnosed cancer type in women, the breast
cancer claims about 370,000 deaths each year around the
world [2]. Surgery, radiotherapy and chemotherapy are
among the most widely used treatment methods for
patients with breast cancer [3-5]. Still, these conventional
treatment modalities did not improve the survival rate of
patients with locally advanced or metastatic breast cancer.
With standard therapy, locally advanced breast cancer has
a five year survival rate of 55 % and a ten year survival rate
of 35 % [6]. There is a 40 % recurrence rate after ten years
following the diagnosis and removal of primary tumor in
patients with breast cancer [7]. For all these reasons, novel
treatment methods are needed for the treatment of
patients with breast cancer.
Induction of programmed cell death known as apoptosis
[8], appears to be a viable alternative to currently
employed treatment modalities in the fight against cancer
[9]. In order for chemotherapy and radiotherapy treat-
ment options to work as anticancer agents; tumor sup-
pressor gene, p53, is required [10]. Unfortunately, p53
mutations are acquired during the progression of cancer
in more than half of the human tumors [11,12]. There-
fore, the resistance to both chemotherapy and radiother-
apy is almost unavoidable in tumors lacking p53 [13]. On
the other hand, death ligands are capable of inducing
apoptosis independently of p53 status of cells [14].
Because of this reason, death ligands are currently consid-
ered as anticancer agents [15]. Among the death ligands
tested, Tumor Necrosis Factor (TNF) [16-18] and FasL
[19] effectively induced apoptosis in cancer cells. How-
ever, due to their systemic toxicity, the application of these
agents in cancer gene therapy is very limited. The discov-
ery of a novel death ligand, TRAIL [20,21], changed this
view, since unlike other members of the TNF family,
TRAIL selectively killed cancer cells without causing any
harm to normal cells [22]. Thus, treating tumor cells with
TRAIL ligand appeared as an invaluable way of inducing
apoptosis specifically in tumor cells, as normal cells are
protected against the death-inducing effects of TRAIL
[23,24]. However, the mechanism of TRAIL resistance in
normal cells is not understood [25] and significant pro-
portions of cancer cells [26] including those of breast
[27,28] appeared to be TRAIL resistant. Consequently,
TRAIL resistance constitutes a barrier if one wishes to use
TRAIL as a death ligand in any breast cancer gene therapy
approach.
Resistance to TRAIL-induced apoptosis in normal cells
was initially considered to be caused by the presence of
decoy receptors (TRAIL-R3 and TRAIL-R4), which com-
pete with death receptors (TRAIL-R1 and TRAIL-R2) for
binding to TRAIL [29,30]. So far, no correlation between
TRAIL sensitivity and the expression pattern of TRAIL
receptors has been demonstrated in cancer cells yet [31].
The presence of intracellular apoptosis inhibitory sub-
stances (bcl-xL, c-FLIP, cIAP etc.) was also blamed to be
responsible for TRAIL resistance [31-33]. Intriguingly, the
engagement of both TRAIL death receptors and TRAIL-R4
decoy receptor also activated NF-kB pathway [24,34,35].
Because NF-kB activation is known to hamper the apop-
totic pathways in cells by up-regulating the expression of
various apoptosis inhibitory molecules such as cFLIP, bcl-
xL, c-IAP and the decoy receptor TRAIL-R3 [34,36,37],
high levels of NF-kB activation might be a strong factor
responsible for blocking apoptotic processes in order to
establish TRAIL resistance. For this reason, we analyzed
both the TRAIL induced as well as endogenous NF-kB
activities using Luciferase reporter gene assays in MCF7
breast cancer cells. Because TRAIL-R1, TRAIL-R2 and
TRAIL-R4 induced NF-kB activation has been shown to be
primarily mediated by TRAF2-NIK-IkappaB kinase alpha/
beta signaling cascade [35], MCF7 breast cancer cells were
coinfected with adenovirus vectors encoding a dominant
negative mutant to IKKβ (AdIKKβ KA) [38] and hTRAIL
(Ad5hTRAIL) in order to test if TRAIL resistance in breast
cancer cells is eliminated through the inhibition of IKK, a
leading modulator of NF-kB. The molecular mechanism
of TRAIL resistance in breast cancer cells (MCF7 and
MDA-MB-231) was studied by novel Real Time RT-PCR
assays and conventional flow cytometry in order to verify
if there is any relationship between TRAIL resistance and
the expression pattern of TRAIL receptors. Lastly, a DcR2
siRNA approach was utilized to knock down the expres-
sion of relevant TRAIL decoy receptor in order to reveal its
connection to TRAIL resistance.
Methods
Recombinant adenovirus vector production
Amplification of the vectors Ad5hTRAIL [39], AdIKKβ KA
[17], AdEGFP [18], AdCMVLacZ [40] and AdNFkBLuc
[38] was performed as previously described [41]. Ampli-
fied vectors were stored at -80°C in 10 mM Tris with 20 %
glycerol. AdIKKβ KA expresses a dominant negative
mutant of IKKβ , which interacts with other IKK subunits
to form inactive IKK complexes. The particle titers of ade-
noviral stocks were in the range of 1013 DNA particles/ml,
whereas the typical particle/plaque forming unit ratio was
equal to 50.BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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Infection of breast cancer cells with first generation 
recombinant adenovirus vectors
Breast cancer cell lines were cultured in RPMI 1640
medium supplemented with 10 % FBS, 2.2 g/l sodium
bicarbonate, 1 mM L-glutamine, and 1 % penicillin-strep-
tomycin mixture, at 37°C in a humidified 5 % CO2
atmosphere. Experimental steps of transduction of breast
cancer cells with adenoviral vectors can be summarized as
follows: Breast cancer cells were infected with an increas-
ing multiplicity of infection (MOI) of AdEGFP (vector
expressing enhanced green fluorescent protein (EGFP)
reporter gene) vector at 37°C in RPMI 1640 without FBS.
Two hours following infection, equal volume of RPMI
1640 supplemented with 20 % FBS was added to increase
the serum concentration in the media to 10 %. 48 hours
after the infection, the level of transduction was detected
by examining of the percentage of GFP (+) cells under a
fluorescent microscopy and subsequently by flow cytom-
etry. Propidium iodide exclusion technique was used to
determine the cell viability. Overexpression of hTRAIL
was provided by Ad5hTRAIL infection. Cells were coin-
fected with adenovirus vectors encoding IKKβ  dominant
negative mutant (AdIKKβ KA) and Ad5hTRAIL in order to
block IKK activity thereby NF-kB activation. NF-kB pro-
moter based Luciferase assay system was utilized to con-
duct NF-kB transcription activation assays using
AdNFkBLuc construct. AdCMVLacZ vector was used as a
control.
NF-kB directed transcription activation assays
AdNFkBLuc construct was utilized in order to determine
the NF-kB activation status of MCF7 cells. AdNFkBLuc
vector [38] possesses four tandem copies of the NF-kB
consensus sequence fused to a TATA-like promoter from
the herpes simplex virus-thymidine kinase gene driving
the expression of a Luciferase reporter. Transcriptional
induction mediated by NF-kB in the presence or absence
of TRAIL was measured according to the manufacturer's
protocol using the Luciferase assay system with Reporter
Lysis Buffer (Promega, Inc.). All measurements of Luci-
ferase activity expressed as relative light units were nor-
malized against the protein concentration.
Cell viability assays
Discrimination of live cells from dead cells was performed
using Live/Dead Cellular Viability/Cytotoxicity Kit from
Molecular Probes (Eugene, OR). This assay is based on the
use of Calsein AM and Ethidium homodimer-1 (EthD-1).
Calsein AM is a fluorogenic substrate for intracellular cal-
sein esterase. It is modified to a green fluorescent com-
pound (calsein) by active esterase in live cells with intact
membranes, thus serves as a marker for viable cells.
Unharmed cell membranes do not allow EthD-1, a red
fluorescent nucleic acid stain, to enter inside the cell.
However, cells with damaged membrane uptake the dye
and stain positive.
Apoptosis detection by Annexin V binding
Annexin V conjugated to fluorochromes such as FITC has
successfully been used as probes to detect cells undergo-
ing apoptosis. Annexin V binding assays were carried out
according to manufacturer's instructions (Alexis Biochem-
icals). For this purpose, a FITC conjugated mouse mono-
clonal antibody to human Annexin V (ALX-804-100F-
T100) was employed to detect apoptotic cells via flow
cytometry.
The detection of TRAIL receptor expression profile by flow 
cytometry
Anti-TRAIL receptor flow cytometry set (Cat. ALX-850-
273-KI01) was used to detect TRAIL receptor protein
expression on cell surface. This kit contains 100µgs of
MAb to TRAIL-R1 (clone HS101, Cat. 804-297A), -R2
(clone HS201, Cat.804-298A), -R3 (clone HS301, Cat.
804-344A) and -R4 (clone HS402, Cat. 804-299A). Pri-
mary antibodies were used at 5 µg/ml concentration.
Biotinylated goat anti-mouse IgG1 (Cat. ALX-211-202)
was used as a secondary antibody followed by streptavi-
din-PE (Cat. ANC-253-050) prior to flow cytometry. Flow
analysis was performed according to manufacturer's pro-
tocols using BD FACSCALIBUR at the Akdeniz University
Hospitals. Purified mouse IgG1 (MOPC 31C, Cat. ANC-
278-010) served as an isotype control.
Quantitative Real Time RT-PCR assay for human TRAIL 
receptors
TRIzol reagent (Life Technologies, Gaithersburg, MD) was
used to extract total RNA from breast cancer cells, accord-
ing to the instructions from the manufacturer. Reverse
transcription of 2 µg of total RNA was performed using
TaqMan Reverse Transcription Reagents (Applied Biosys-
tems Cat. N8080234). Despite the fact that the sequences
for TRAIL-R1 and TRAIL-R2 primers and probes were
recently described by our group [42], we had to design
new probe sets for the decoy receptors. Following is the
sequence information for TRAIL decoy receptor sets:
TRAILR3-5'  CCC-TAA-AGT-TCG-TCG-TCG-TCA-T,
TRAILR3-3' GGG-CAG-TGG-TGG-CAG-AGT-A, TRAILR3
Probe: 5' 6FAM-TCGCGGTCCTGCTGCCAGTCCTAGC-
TAMRA 3'; TRAILR4-5'  ACA-GAG-GCG-CAG-CCT-CAA,
TRAILR4-3'  ACG-GGT-TAC-AGG-CTC-CAG-TAT-ATT,
TRAILR4 Probe: 5' 6FAM-AGGAGGAGTGTCCAGCAG-
GATCTCATAGATC-TAMRA 3'. rRNA was amplified as an
internal control in the same reaction. Both the rRNA
primers and probes were obtained from PE Applied Bio-
systems (Cat. 4308329). ∆∆ Ct method was used as
described by Applied Biosystems to calculate the relative
quantities of TRAIL receptors. The TaqMan PCR reactionBMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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was performed as described by the manufacturer (Applied
Biosystems Cat. N8080228).
A DcR2 siRNA approach targeting TRAIL-R4 expression
Posttranscriptional silencing of gene expression became a
very useful approach within the last couple of years in
research. DcR2 siRNA experiments were performed using
DcR2 siRNA (sc-35185), siRNA transfection medium (sc-
36868) and siRNA transfection reagent (sc-29528) in
MCF7 breast cancer cells as described by the manufacturer
(Santa Cruz Biotechnology). Flow cytometry analysis was
performed to assess any changes in TRAIL-R4 gene expres-
sion. MCF7 cells were infected with Ad5hTRAIL or AdCM-
VLacZ vectors at increasing doses 35 hours following the
transfection. Molecular Probe's Live/Dead Cellular Viabil-
ity/Cytotoxicity Kit was used to assess the amount of live
cells 48 hours following the infection.
Results
MCF7 breast carcinoma cells were efficiently transduced 
with recombinant adenoviruses
In order to find out the efficacy of transduction of breast
cancer cells by first generation adenoviral vectors, MCF7
cells were infected with increasing Multiplicity of Infec-
tion (MOI) of adenovirus encoding Enhanced Green Flu-
orescent Protein (AdEGFP). The transduction profiles
were followed under fluorescent microscopy and the
results were quantitatively analyzed by flow cytometry 48
hours following the infection (Figure 1). While an MOI of
5000 DNA particles/cell was sufficient to transduce more
than 90 % of the cells, nearly 100 % of the cells were trans-
duced with AdEGFP at an MOI of 10,000 DNA particles/
cell. These assays were also pivotal in obtaining the opti-
mum dose of adenovirus required for efficient transduc-
tion of MCF7 breast carcinoma cell line without observing
deleterious cytotoxic effects. These results demonstrated
that breast cancer cells were transduced successfully with
recombinant adenoviral vectors.
MCF7 breast cancer cells displayed complete resistance to 
TRAIL
Although TRAIL appeared as a promising therapeutic lig-
and to treat cancer, a variety of tumor types were reported
to be resistant to TRAIL-induced cell death. For this rea-
son, we wanted to investigate if exogenous TRAIL expres-
sion delivered by adenovirus vectors would induce killing
of breast cancer cells. To test this, MCF7 cells were infected
with increasing titers of Ad5hTRAIL or AdCMVLacZ.
Amount of viable cells were detected using Molecular
Probe's Live/Dead Cellular Viability/Cytotoxicity Kit 48
hours following the infections (Figure 2). MCF7 cells dis-
played complete resistance to TRAIL, as no reduction in
the level of viable cells was observed even at an MOI of
10,000 DNA particles/cell, at which almost all cells were
infected. Thus, it was concluded that MCF7 breast cancer
cells were completely resistant to adenovirus delivery of
TRAIL. Similarly, AdCMVLacZ infection alone revealed no
significant degree of cell death either (data not shown).
Blocking IKK induced NF-kB activation pathway alone did 
not cause any reduction in the viability of MCF7 breast 
carcinoma cells
Because increased NF-kB activity was claimed to be
responsible for the resistance to death ligand induced
cytotoxicity in some tumors [36,37], we wanted to test if
the inhibition of IKK activity thereby NF-kB would reduce
the viability of breast cancer cells. In order to block the
intracellular anti-apoptotic NF-kB pathway, MCF7 cells
were infected with increasing MOIs of adenoviral vectors
encoding a dominant negative mutant of
IKKβ (AdIKKβ KA), a key molecule involved in the activa-
tion of NF-kB. Cell viability was examined 48 hours fol-
lowing the infection under fluorescent microscope (Figure
2). Interestingly, AdIKKβ KA vector alone proved ineffi-
cient in reducing the viability of MCF7 cells, even at an
MOI of 10,000 DNA particles/cell.
Adenovirus delivery of IKKβ KA gene expression sensitized 
MCF7 breast cancer cells to TRAIL-induced apoptosis
Adenovirus-mediated delivery of IKKβ  (Ad.IKKβ KA)
[17,18] or IkBα  (Ad.IkBα SR) [40,43] dominant negative
mutants have previously been demonstrated to sensitize
lung cancer cells to TNF death ligand. Because most of the
breast cancer cell lines tested appeared to be TRAIL resist-
ant [27,28], NF-kB targeting strategies involving IKK inhi-
bition was employed to verify whether MCF7 breast
carcinoma cells were sensitized to TRAIL under these cir-
cumstances. To accomplish this, MCF7 cells were coin-
fected with a constant MOI of Ad5hTRAIL construct and
increasing doses of AdIKKβ KA vector. In order to better
assess the sensitization phenomenon, Ad5hTRAIL was
infected at two different MOIs into MCF7 breast cancer
cell lines. While a constant MOI of 1000 DNA particles/
cell of Ad5hTRAIL was used in infection experiments
depicted on Figure 3, infection experiments conducted at
an MOI of 5000 DNA particles/cell are displayed in Figure
4. The amount of viable cells was detected 48 hours fol-
lowing the infections using Molecular Probe's Live/Dead
Cellular Viability/Cytotoxicity Kit. Intriguingly, MCF7
cells were sensitized to TRAIL only when Ad5hTRAIL was
coinfected with AdIKKβ KA vector. For instance, nearly 55
% cell death was observed when cells were coinfected with
1000 MOI of Ad5hTRAIL and 5000 MOI of AdIKKβ KA
constructs (Figure 3). When MOI of Ad5hTRAIL was
increased to 5000 as depicted on Figure 4, the death rate
went up to 90 %. On the other hand, AdCMVLacZ infec-
tion instead of AdIKKβ KA in breast cancer cells revealed
no TRAIL sensitization (data not shown). These results
suggested that IKKβ KA expression via adenoviral vectorsBMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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First generation adenoviral vectors efficiently transduced MCF7 breast cancer cells Figure 1
First generation adenoviral vectors efficiently transduced MCF7 breast cancer cells. MCF7 cells were infected with increasing 
MOIs of AdEGFP for 48 hours prior to analysis. The number of EGFP expressing cells was detected under fluorescent micros-
copy (Panel A), and analyzed by flow cytometry (Panel B). Numbers represent viral doses applied in MOI values as DNA 
particles/cell.BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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defeated TRAIL resistance observed in MCF7 breast cancer
cells.
Exogenous TRAIL overexpression elevated the basal NF-
kB activity in MCF7 cells, whereas IKKβ KA expression 
blocked both TRAIL-induced and basal NF-kB activities
It is well known that different tumor cells display diverse
levels of endogenous NF-kB activities. Furthermore, intra-
cellular NF-kB activity in tumor cells is upregulated by
both TRAIL death receptors (TRAIL-R1 and TRAIL-R2)
[34,44] as well as TRAIL decoy receptor TRAIL-R4 [45]
upon ligand binding. Knowing the endogenous NF-kB
status of cancer cells before the therapy is obviously cru-
cial for TRAIL mediated gene therapy targeting to induce
apoptosis in cancer cells. A coinfection experiment was
performed using a recombinant adenovirus vector carry-
ing NF-kB driven Luciferase reporter gene (AdNFkBLuc)
and Ad5hTRAIL vector in order to study the extent of NF-
kB activation as a result of TRAIL overexpression in MCF7
breast cancer cell line. NF-kB Luciferase assays were con-
ducted 24 hours following the infection in order to deter-
mine cell's NF-kB activation status. As seen in Figure 5,
Ad5hTRAIL at an MOI of 5000 DNA particles/cell (Panel
B) but not at an MOI of 1000 DNA particles/cell (Panel A)
stimulated NF-kB activation. In order to determine the
magnitude of NF-kB inhibition, a triple coinfection exper-
iment involving AdNFkBLuc, Ad5hTRAIL and AdIKKβ KA
or AdCMVLacZ was performed. While IKKβ KA overex-
pression in MCF7 cells gradually reduced both the TRAIL-
induced and basal NF-kB activities in MCF7 cells, no such
NF-kB inhibiting effect was observed in cells upon super-
infection with AdCMVLacZ virus as a control (Figure 5).
Coinfection of Ad5hTRAIL and AdIKKβ KA results in 
apoptotic cell death in MCF7 breast cancer cells
To show that apoptosis is the mechanism of cell death
mediated by TRAIL overexpression under the setting of
IKK inhibition in MCF7 cells, Annexin V staining was per-
formed using flow cytometry. For this purpose, MCF7
cells were infected with Ad5hTRAIL or AdIKKβ KA vectors
alone or in combination. Thirty-five hours following the
infection, apoptotic cell death was analyzed by Annexin-
V-FITC staining. As displayed in Figure 6 Panel A, there
was no substantial Annexin V binding generated by the
expression of TRAIL or IKKβ KA in MCF7 cells. However,
considerable levels of Annexin V binding were observed in
cells coinfected with Ad5hTRAIL and AdIKKβ KA indicat-
ing apoptotic cell death (Figure 6, Panel B). As predicted,
Ad5hTRAIL and AdCMVLacZ (negative control) coinfec-
tion did not yield any significant levels of Annexin V bind-
ing as MCF7 cells are resistant to TRAIL in the absence of
IKK inhibition. These results suggested that the
Ad5hTRAIL or AdIKKβ KA infection alone did not decrease the viability of MCF7 breast cancer cells Figure 2
Ad5hTRAIL or AdIKKβ KA infection alone did not decrease the viability of MCF7 breast cancer cells. MCF7 cells were infected 
with increasing MOIs of either Ad5hTRAIL or AdIKKβ KA construct. Cell viability was detected using Molecular Probe's Live/
Dead Cellular Viability/Cytotoxicity Kit 48 hours following the infection. Numbers represent viral doses applied, in MOI values 
as DNA particles/cell.BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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IKKβ KA expression via adenoviral vectors sensitized MCF7 cells to TRAIL-mediated apoptosis Figure 3
IKKβ KA expression via adenoviral vectors sensitized MCF7 cells to TRAIL-mediated apoptosis. MCF7 cells were infected with 
increasing doses of adenoviral vectors encoding dominant negative mutant of IKKβ  (as shown below each panel), while simulta-
neous infection with Ad5hTRAIL (as shown above each panel) was performed at a constant MOI of 1000. Cell viability was 
detected using Molecular Probe's Live/Dead Cellular Viability/Cytotoxicity Kit 48 hours following infection. Numbers repre-
sent viral doses applied in MOI values as DNA particles/cell. Fluorescent micrographs are provided in Panel A; Panel B depicts 
quantitative analysis of such infections. Values represent the mean (± SEM) of three different experiments.BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
Page 8 of 17
(page number not for citation purposes)
AdIKKβ KA infection defeated the resistance to TRAIL-induced apoptosis in MCF7 breast cancer cells Figure 4
AdIKKβ KA infection defeated the resistance to TRAIL-induced apoptosis in MCF7 breast cancer cells. These cells were coin-
fected with a constant MOI of 5000 DNA particles/cell of Ad5hTRAIL (as shown above each panel) and increasing doses of 
AdIKKβ KA (as shown below each panel). Live/Dead Cellular Viability/Cytotoxicity Kit from Molecular Probe was used to 
detect TRAIL cytotoxicity 48 hours following infection. Numbers represent viral doses applied, in MOI values as DNA parti-
cles/cell. Data represent the mean of (± SEM) six independent data points (n = 6).BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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Distinctive regulation of NF-kB activation in MCF7 breast cancer cells by Ad5hTRAIL and/or AdIKKβ KA infections Figure 5
Distinctive regulation of NF-kB activation in MCF7 breast cancer cells by Ad5hTRAIL and/or AdIKKβ KA infections. MCF7 cells 
were simultaneously infected with AdNFkBLuc, Ad5hTRAIL and/or increasing doses of AdIKKβ KA construct for 24 hours. 
AdCMVLacZ infection was also performed as a negative control. The types of constructs used in the infection are shown on 
the x axis. MOI values represent DNA particles/cell. Ad5hTRAIL vector was used at two different constant MOIs (MOI of 
1000 and 5000) in order to avoid cell death complicating our assay result. Luciferase activity expressed in Relative Light Units 
per microgram protein is shown on y axis. Values represent the mean (± SEM) of six independent data points (n = 6).BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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Ad5hTRAIL and AdIKKβ KA coinfection induced apoptosis in MCF7 breast carcinoma cells Figure 6
Ad5hTRAIL and AdIKKβ KA coinfection induced apoptosis in MCF7 breast carcinoma cells. FITC conjugated Annexin V and 
Propidium Iodide (PI) staining were utilized using MCF7 cells infected with various combinations of adenovirus constructs as 
described in Methods prior to flow cytometry. Each histogram represents 104 gated MCF7 cells. Histograms were illustrated in 
two panels for clarity. Various treatment settings were provided in Panel A. MOI of 5000 DNA particles/cell was used for each 
viral construct unless stated otherwise in the Figure. Control line represents uninfected but FITC-Annexin V and PI stained 
MCF7 cells. Only one representative assay out of three independent assays was provided.BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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mechanism of cell death experienced by MCF7 cells is
apoptosis following TRAIL stimulation under the setting
of IKK inhibition.
MCF7 breast cancer cell line displayed significant levels of 
TRAIL decoy receptor-4 expression
So far no evidence of the connection between the expres-
sion pattern of TRAIL receptors and TRAIL sensitivity was
found in cancer cells [31]. Part of the reason might have
been the inability to screen all TRAIL receptors at once in
breast cancer cells then [28]. In order to compensate this
deficiency, quantitative novel Real Time RT-PCR assays
were conducted using primer-probe sets specifically
designed to detect each TRAIL receptor in MCF7 breast
cancer cells (Figure 7, Panel A). According to our results,
while all TRAIL receptors were expressed in MCF7 cells,
TRAIL-R4 expression was the highest among the four. In
addition, the level of TRAIL-R2 expression was much
higher than that of TRAIL-R1. Lastly, TRAIL-R3 decoy
receptor expression was the lowest. These results sug-
gested that high levels of TRAIL-R4 decoy receptor expres-
sion correlated well with TRAIL resistance. However, as
the gene expression detected inside the cell may not nec-
essarily correlate with the receptor expression on cell sur-
face, we decided to perform flow cytometry analysis using
antibodies specific to four different TRAIL receptors. As
shown in Figure 7 Panel B, MCF7 cells expressed all TRAIL
receptors excluding TRAIL-R3 on cell surface. While simi-
lar levels of TRAIL death receptors TRAIL-R1 and TRAIL-
R2 were expressed, there were still considerable levels of
TRAIL-R4 decoy receptor expression on the surface of
MCF7 cells.
TRAIL sensitive MDA-MB-231 cells displayed very low 
levels of TRAIL-R4 decoy receptor expression on cell 
surface
In order to solidify the importance of TRAIL-R4 expres-
sion and its connection to TRAIL resistance, another
breast cancer cell line, MDA-MB-231, was also analyzed in
terms of TRAIL receptor expression profile. Real Time RT-
PCR assays revealed that while TRAIL-R2 expression was
the highest on transcript levels, TRAIL-R4 decoy receptor
expression was the lowest TRAIL receptor expressed in
MDA-MB-231 breast cancer cells (Figure 8, Panel A). Fur-
thermore, flow cytometry analysis indicated that insignif-
icant levels of TRAIL-R4 expression were detected on the
surface of MDA-MB-231 breast cancer cells (Figure 8,
Panel B). TRAIL-R3 decoy receptor expression, however,
was not detectable using flow cytometry. Intriguingly, in
contrast to what was observed with MCF7, adenovirus
delivery of TRAIL alone killed significant proportions of
MDA-MB-231 breast cancer cells (Figure 9).
Lowering of TRAIL-R4 gene expression sensitized MCF7 
breast cancer cells to TRAIL
In order to solidify the connection between TRAIL-R4
decoy receptor gene expression and TRAIL resistance, a
DcR2 siRNA approach was executed in TRAIL resistant
MCF7 breast cancer cells. Flow cytometry analysis con-
ducted 35 hours following the transfection revealed that
the level of TRAIL-R4 protein expression on surface went
down drastically (Figure 10, Panel A). At this stage, MCF7
cells were further infected with either Ad5hTRAIL or AdC-
MVLacZ vector at increasing doses. Cell viability assays
were conducted 48 hours following the infection. Only
Ad5hTRAIL infected cells exhibited considerable amount
of cell death following transfection (Figure 10, Panel B).
No such effect was observed when cells were infected with
AdCMVLacZ virus (data not shown).
Discussion
Although, conventional treatment modalities could not
satisfactorily improve the survival rates of patients with
locally advanced and metastatic disease, adenovirus deliv-
ery of death ligands represents a feasible choice for the
treatment of patients with breast cancer. However, recent
observations demonstrating that a considerable portion
of human cancers including those of the breast [27,28]
were TRAIL resistant undermined the potential applica-
tion of TRAIL against cancer. Accordingly, the understand-
ing of the mechanism of TRAIL resistance is the key to
resolve primary obstacles in TRAIL mediated gene therapy
approach. Based on recent findings from our laboratory
and others, we think that NF-kB signaling is one of the
most crucial pathways involved in the constitution of
TRAIL resistance [26]. Despite the fact that TRAIL-R1,
TRAIL-R2 and TRAIL-R4 induced NF-kB activation has
been shown to be primarily mediated by TRAF2-NIK-Ika-
ppaB kinase alpha/beta signaling cascade [35], there is
some doubt on whether or not NF-kB activation can block
TRAIL mediated apoptosis. For example, in one particular
study it was reported that NF-kB inhibition by way of Ika-
ppaBalpha mutant expression sensitized MCF7 cells to
TNF but not TRAIL-induced apoptosis [35]. Considering
the fact that there are different ways to activate NF-kB
pathway (IkB dependent and independent ways) [46] we
decided to inhibit IKK activity rather than targeting Ikap-
paBalpha itself to look for the possibility of sensitizing
MCF7 breast cancer cells to TRAIL.
First of all, in order to find out the efficacy of adenovirus
transduction in breast cancer cells, MCF7 cells were
infected with increasing MOIs of AdEGFP virus. The
transduction profiles analyzed by flow cytometry showed
that nearly 100 % of the cells were transduced with
AdEGFP at an MOI of 10,000 DNA particles/cell (Figure
1). The efficacy of TRAIL in mediating apoptosis of MCF7
breast cancer cells was assessed using Ad5hTRAILBMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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MCF7 breast carcinoma cell line displayed substantial levels of TRAIL-R4 decoy receptor expression Figure 7
MCF7 breast carcinoma cell line displayed substantial levels of TRAIL-R4 decoy receptor expression. Quantitative Real Time 
RT-PCR of TRAIL receptors was performed as described in Methods (Panel A). TRAIL receptor levels per 25 pg of ribosomal 
cDNA are presented in the graph for clarity. Ribosomal RNA primers and probes were included in each TaqMan reaction as an 
internal control. Panel B depicts the surface TRAIL receptor expression pattern of MCF7 cells using flow cytometry. Experi-
mental parameters are defined in colored lines. 104 cells were gated for each histogram. Only one representative assay for each 
experiment (independently repeated three times) is shown.BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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MDA-MB-231 breast cancer cells displayed trivial levels of TRAIL-R4 decoy receptor expression on surface Figure 8
MDA-MB-231 breast cancer cells displayed trivial levels of TRAIL-R4 decoy receptor expression on surface. TRAIL receptor 
composition of MDA-MB-231 breast cancer cells revealed by Real Time RT-PCR assay is displayed in Panel A. Panel B illus-
trates flow cytometry analysis showing the surface expression pattern of TRAIL receptors. 104 cells were gated for each histo-
gram. Only one representative assay out of three is shown.BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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construct. Interestingly, MCF7 cells displayed complete
resistance to TRAIL as no reduction in the level of viable
cells was observed even at an MOI of 10,000 DNA parti-
cles/cell (Figure 2). IKK inhibiting strategy alone proved
inefficient in reducing the viability of MCF7 cells suggest-
ing that an apoptotic stimulus was required in order to
induce cell killing (Figure 2). Interestingly, in order to
break down TRAIL resistance and to induce cell death, a
coinfection of MCF7 cells with Ad5hTRAIL and
AdIKKβ KA was required (Figures 3 and 4). Luciferase
assays confirmed that both the TRAIL induced and endog-
enous NF-kB activities were drastically reduced by the
infection of MCF7 cells with AdIKKβ KA virus (Figure 5).
Moreover, IKKβ KA sensitization of MCF7 breast carci-
noma cells resulted in TRAIL induced apoptosis as
revealed by Annexin V binding assays (Figure 6). These
results suggested that NF-kB activation pathway has a
hampering effect on TRAIL-induced cell death in MCF7
cells, and blocking this pathway is essential to sensitize
breast cancer cells to TRAIL mediated apoptosis.
So far, no correlation between TRAIL resistance and TRAIL
decoy receptor gene expression has been reported. For
example, analysis of breast cancer cell lines by just exam-
ining the expression levels of TRAIL death receptors
(TRAIL-R1 and TRAIL-R2) and TRAIL-R3 decoy receptor
using RNase protection assay did not reveal any connec-
tion between the expression pattern of TRAIL receptors
and TRAIL resistance [28]. But whether or not TRAIL-R4
decoy receptor gene expression in any way contributes to
MDA-MB-231 breast cancer cell line is sensitive to Ad5hTRAIL infection Figure 9
MDA-MB-231 breast cancer cell line is sensitive to Ad5hTRAIL infection. MDA-MB-231 breast cancer cells were infected with 
increasing MOIs of Ad5hTRAIL construct. Molecular Probe's Live/Dead Cellular Viability/Cytotoxicity Kit was used to detect % 
viable cells 48 hours following the infection. Numbers represent viral doses applied in MOI values as DNA particles/cell. Values 
represent the mean (± SEM) of six independent data points (n = 6).BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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Knocking down TRAIL-R4 expression sensitized MCF7 breast cancer cells to TRAIL Figure 10
Knocking down TRAIL-R4 expression sensitized MCF7 breast cancer cells to TRAIL. A DcR2 siRNA approach was adminis-
tered as described in Methods using TRAIL resistant MCF7 breast cancer cell line. Panel A depicts a flow cytometry analysis 
confirming strong attenuation of TRAIL-R4 expression on cell surface. TRAIL-R2 death receptor expression was also detected 
as a control. Sensitization of MCF7 breast cancer cells to TRAIL following a DcR2 siRNA approach is provided in Panel B. 
MCF7 breast cancer cells were infected with increasing doses of Ad5hTRAIL alone following a DcR2 siRNA transfection. Cell 
death was detected 48 hours following the infection (Panel B). Data represent the mean (± SEM) of 6 independent data points.BMC Cancer 2005, 5:54 http://www.biomedcentral.com/1471-2407/5/54
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TRAIL resistance in breast cancer cells remains to be tested
yet. Quantitative Real Time RT-PCR assays were
developed in order to assess the level of TRAIL receptor
gene expression in breast carcinoma cells. While all TRAIL
receptors were detectable in MCF7 breast carcinoma cell
line, the level of TRAIL-R4 decoy receptor gene expression
was the highest among the four (Figure 7, Panel A). This
intriguing observation is consistent with a previous report
suggesting that transient TRAIL-R4 overexpression
protected target cells from TRAIL induced cytotoxicity
[45]. TRAIL R4 is known to protect cells from apoptosis by
acting both as a decoy receptor and an antiapoptotic sig-
nal provider. While Real Time PCR assay is useful in
assessing the level of gene expression on mRNA levels,
obviously this assay does not necessarily reflect TRAIL
receptor composition on cell surface. For this reason, con-
ventional flow cytometry analysis was carried out in order
to determine the level of TRAIL receptor protein expres-
sion on cell surface. Despite the presence of TRAIL death
receptors, substantial levels of TRAIL-R4 decoy receptor
expression were detectable on the surface of MCF7 breast
carcinoma cells (Figure 7, Panel B). On top of that, TRAIL
sensitive MDA-MB-231 cell line (Figure 9) displayed very
low levels of TRAIL-R4 decoy receptor expression on cell
surface (Figure 8, Panel B). Neither of the cell lines
expressed detectable levels of TRAIL-R3 decoy receptor on
surface. Intriguingly, administration of a DcR2 siRNA
approach lowered surface TRAIL-R4 expression and sensi-
tized MCF7 breast cancer cells to TRAIL (Figure 10).
Conclusion
Our results demonstrated that the expression of TRAIL-R4
decoy receptor but not TRAIL-R3 appeared to correlate
well with TRAIL resistance phenotype observed in MCF7
breast cancer cells. Further screening of another breast
cancer cell line, MDA-MB-231, revealed that low levels of
TRAIL-R4 expression on surface were correlated with
TRAIL sensitivity. These results strengthen our argument
that TRAIL-R4 but not TRAIL-R3 is the decoy receptor
which appeared to influence TRAIL sensitivity in breast
cancer cells. This is further confirmed by a DcR2 siRNA
assay which suggested that down regulation of TRAIL-R4
expression sensitized MCF7 breast cancer cells to TRAIL.
In addition, the inhibition of IKK pathway thereby NF-kB
sensitized MCF7 cells to TRAIL induced apoptosis despite
the expression of TRAIL-R4 decoy receptor on cell surface.
Consequently, this complementary gene therapy
approach involving IKK inhibition might be necessary to
breakdown TRAIL resistance encountered in patients with
breast cancer.
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